Main Speakers & Final Program
Click on the photos below for more information and follow on Twitter!
Final Program for IFNL2022- (Hawaii time zone)
Saturday, September 24 | |||||
Interferon Lambda: Inflammation and Infection in Experimental Models | |||||
Moderator: Juan Mendoza, University of Chicago, USA | |||||
Session 1 | start | presenter | affiliation | in person/virtual | title |
1 | 8.00 | Mila Prokunina-Olsson | National Cancer Institute, USA | in-person | OPENING REMARKS |
2 | 8.05 | Nabiha Yusuf | University of Alabama at Birmingham, USA | virtual from US | INTERFERON LAMBDA SIGNALING RESTRAINS DEVELOPMENT OF EXPERIMENTAL AUTOIMMUNE ENCEPHALITIS |
3 | 8.18 | Da’ Kuawn Johnson | University of Maryland School of Medicine, USA | virtual from US | AGE-DEPENDENT ROLE OF INTERFERON LAMBDA IN AN INFANT MOUSE MODEL OF BORDETELLA PERTUSSIS INFECTION |
4 | 8.31 | Ryan Martinez | University of Minnesota, USA | virtual from US | TYPE III INTERFERON DRIVES THYMIC B CELL ACTIVATION AND CENTRAL TOLERANCE |
5 | 8.44 | Megan Baldridge | Washington University School of Medicine in St. Louis, USA | in-person | CELLULAR CROSSTALK BY IFN-LAMBDA CONTROLS ENTERIC MURINE NOROVIRUS |
6 | 9.07 | Priyanka Talukdar | University of Pittsburgh School of Public Health, USA | in-person | INTERFERON LAMBDAS ARE EXPRESSED IN TUBERCULOSIS GRANULOMAS AND PROMOTE MACROPHAGE ANTIMYCOBACTERIAL ACTIVITY |
7 | 9.20 | Charlotte Odendall | King’s College London, UK | in-person | INTERFERON: TUG OF WAR BETWEEN HOST AND PATHOGEN |
8 | 9.43 | Danielle Antos | University of Pittsburgh, USA | in person | INTERFERON LAMBDA ALTERS IMMUNE FUNCTION DURING INFLUENZA, BACTERIA SUPER-INFECTION |
9 | 9.56 | Ivan Zanoni | Harvard Medical School, Boston Children’s Hospital, USA | in-person | INTERFERON LAMBDA CONTROLS INTESTINAL INFLAMMATION |
10.20 – 10:50 Coffee/poster break | |||||
Interferon Lambda: COVID-19, Regulation and Tissue Microenvironment | |||||
Moderator: Deanna Santer, University of Manitoba, Canada | |||||
Session 2 | start | presenter | affiliation | in person/virtual | title |
1 | 10.50 | Jordan Feld | Toronto General Hospital Research Institute, Canada | virtual from Canada | PEGYLATED-IFN-LAMBDA AS A THERAPEUTIC FOR COVID-19 |
2 | 11.13 | Emily Hemann | Ohio State University, USA | in-person | INTERFERON-LAMBDA SIGNALING REGULATES DISEASE SEVERITY AND CD8 T CELL IMMUNITY IN A MURINE MODEL OF SARS-COV-2 INFECTION |
3 | 11.26 | Henry Yang | Duke University, USA | virtual from US | INNATE IMMUNE SIGNALING IN TROPHOBLAST AND DECIDUA ORGANOIDS DEFINES DIFFERENTIAL ANTIVIRAL DEFENSES AT THE MATERNAL-FETAL INTERFACE |
4 | 11.38 | Steeve Boulant | University of Florida, USA | in-person | LOW OXYGEN LEVELS IN THE HUMAN GUT INFLUENCES THE IMMUNE FUNCTIONS OF INTESTINAL EPITHELIAL CELLS |
5 | 12.01 | Austin Wright | Oregon Health and Science University, USA | in person | CRISPR SCREENS IDENTIFY INTERFERON REGULATORY FACTOR 6 AS A POTENTIAL REGULATOR OF INTERFERON SIGNALING IN THE INTESTINAL EPITHELIUM |
6 | 12.14 | Emmanuel Thomas | University of Miami School of Medicine, USA | in-person | INTERFERON INDUCED ISGYLATION IS DIFFERENTIALLY REGULATED AS INDUCED-PLURIPOTENT STEM CELLS DIFFERENTIATE TO EPITHELIAL CELLS |
8 | 12.27 | Evangelos Andreakos | Academy of Athens, Greece | in-person | TYPE III IFNS IN ANTIVIRAL IMMUNITY AND BEYOND |
7 | 12.50 | Emily Mesev | Princeton University, USA | in-person | INTRACELLULAR DOMAINS OF TYPE I AND III INTERFERON RECEPTORS ENCODE DIFFERENCES IN JAK-STAT SIGNALING MAGNITUDE |
Sunday, September 25 | |||||
Interferon Lambda: Human Genetic Associations and Molecular Functions | |||||
Moderator: Thomas O’Brien, National Cancer Institute, USA | |||||
Session 3 | start | presenter | affiliation | in person/virtual | title |
1 | 8.00 | Sreedhar Chinnaswamy | National Institute of Biomedical Genomics, India | virtual from India | LEISHMANIA DONOVANI INFECTION INDUCES IFN-Λ3 IN CELLS, MICE, AND HUMANS |
2 | 8.13 | Tsion Minas | National Cancer Institute, USA/Ethiopia | virtual from Ethiopia | HUMAN HERPESVIRUS 8 INFECTION IS ASSOCIATED WITH PROSTATE CANCER AMONG IFNL4-ΔG CARRIERS |
3 | 8.26 | Michelle Fang | National Cancer Institute, USA | virtual from US | NO ASSOCIATION OF IFNL4 GENOTYPE WITH OPPORTUNISTIC INFECTIONS AND MALIGNANCIES AMONG MEN WITH HIV-1 INFECTION |
4 | 8.35 | Francine Baker | National Cancer Institute, USA | virtual from US | EXPLORING THE ASSOCIATION OF IFNL4 VARIANTS WITH THE RISK OF BURKITT LYMPHOMA IN 4000 CHILDREN FROM SUB-SAHARAN AFRICA |
5 | 8.48 | Carolyn Coyne | Duke University, USA | Virtual from US | IFNLs IN SOME OTHER PLACENTAL ORGANOIDS |
6 | 9.11 | Megan Stanifer | University of Florida, USA | in-person | CELL TYPE SPECIFIC RESPONSE TO VIRAL INFECTION IN THE HUMAN GASTROINTESTINAL TRACT |
7 | 9.24 | Mila Prokunina-Olsson | National Cancer Institute, USA | in-person | NEW INSIGHTS INTO MOLECULAR FUNCTIONS OF IFNL4 |
8 | 9.47 | Ram Savan | University of Washington, USA | in-person | THE COMMON IL-10 RECEPTOR CHAIN FINDS SPACE FOR PRIVATE INTERACTIONS AWAY FROM THE CROWD |
10.10 – 10:50 Coffee/poster break | |||||
Interferon Lambda: Crosstalk, Structure and Therapeutics | |||||
Moderator: Rune Hartmann, University of Aarhus, Denmark | |||||
Session 4 | start | presenter | affiliation | in person/virtual | title |
1 | 10.50 | Paul Hertzog | Hudson Institute, Australia | in-person | CROSSTALK BETWEEN TYPE I AND TYPE III INTERFERONS |
2 | 11.13 | Jorna Sojati | University of Pittsburgh School of Medicine, USA | in person | TYPE I AND III INTERFERON DRIVE NON-REDUNDANT AND AIRWAY SITE-SPECIFIC ANTIVIRAL IMMUNE RESPONSES IN HUMAN METAPNEUMOVIRUS INFECTION |
3 | 11.26 | Bibiana Costa | Center for Experimental and Clinical Infection Research, Germany | in-person | HCMV EXPLOITS STING SIGNALING AND COUNTERACTS ISG AND IFN-Β, BUT NOT IFN-Λ1 INDUCTION TO FACILITATE VIRAL GENE EXPRESSION IN MONOCYTE-DERIVED DENDRITIC CELLS |
4 | 11.39 | Noemie Alphonse | King’s College London, UK | in person | TYPE I AND III INTERFERONS AT THE INTERFACE BETWEEN BACTERIAL PATHOGENS AND THEIR HOST |
5 | 12.02 | Deanna Santer | University of Manitoba, Canada | in person | DYSREGULATED INTERFERON-LAMBDA RECEPTOR LEVELS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE |
6 | 12.14 | Juan Mendoza | University of Chicago, USA | in-person | THE ROLE OF JAK-RECEPTOR INTERACTIONS IN TUNING THE ACTIVITY OF TYPE III INTERFERONS |
7 | 12.37 | William Grubbe | University of Chicago, USA | in-person | TOWARDS STRUCTURAL AND FUNCTIONAL STUDIES OF IFN-LAMBDA1-4 USING PROTEIN ENGINEERING AND MOLECULAR DYNAMICS SIMULATIONS |
8 | 12.50 | Sergei Kotenko | Rutgers University, USA | in-person | DEVELOPMENT OF IFN-BASED THERAPEUTICS |
9 | 13.13 | Ivan Zanoni | Harvard Medical School, Boston Children’s Hospital, USA | in-person | CLOSING REMARKS |